ArticleFrontiers in artificial intelligence2026
Artificial intelligence for early endometrial cancer diagnosis using multimodal clinical data: integrating deep learning, explainability, and data privacy.
Article in Frontiers in artificial intelligence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Integrating artificial intelligence and multi-omics data for precision oncology in endometrial cancer: a narrative review.Functional & integrative genomics · 2026Review
- Artificial intelligence in endometrial cancer: multimodal deep learning and future perspectives in precision gynecologic oncology - a structured narrative review.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Early diagnosis of endometrial cancer is critical for improving survival. However, most AI-based methods are developed using single-modality data, and most of them are uninterpretable and do not offer privacy protection, or they completely ignore privacy issues. We propose a multimodal AI framework that utilizes histopathology whole-slide images (WSIs) and clinical data and incorporates both explainability and privacy-aware learning. Methods: Five hundred and twenty-nine patients' data (354 early-stage and 175 advanced-stage) with 794 WSIs and 208,000 image patches were collected for the study. By using a convolutional neural network (CNN), morphological features were extracted from WSIs, and clinical variables were encoded by a multi-layer perceptron, respectively. These two modalities of information (the learned representations) were combined to make the final category prediction. Interpretability was enabled through Grad-CAM and clinical feature attribution, and privacy-aware training was supported by secure parameter aggregation. Results: The multimodal model obtained an accuracy of 0.91 and an AUC of 0.95, thus it exceeded the performance of clinical-only (accuracy = 0.78, AUC = 0.81) and histopathology-only (accuracy = 0.85, AUC = 0.89) models with a considerable increase in sensitivity (0.89) and specificity (0.93). The performance was preserved by privacy-aware learning as well. The net clinical benefit was maximum as per the Decision Curve Analysis. Conclusion: This framework offers a solution that is accurate, interpretable, and privacy-preserving, thus it can act as a diagnostic aid for early endometrial cancer. However, since the model was developed and evaluated using only the TCGA-UCEC cohort, external multi-center validation is required to confirm generalizability across diverse clinical populations, imaging protocols, and laboratory conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.